{"filing":{"accession_number":"0001193125-26-277631","cik":"0001501989","ticker":"CTMX","company_name":"CytomX Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"d154321d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312526277631/d154321d8k.htm"},"events":[{"id":12843,"run_id":11398,"accession_number":"0001193125-26-277631","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"CytomX held its Annual Meeting on June 17, 2026, with stockholders voting on seven proposals including election of Class II directors (Matthew P. Young and Elaine V. Jones Ph.D.), ratification of Ernst \u0026 Young LLP as auditor, authorization of additional common shares, amendments to the 2015 Equity Incentive Plan and Employee Stock Purchase Plan, advisory approval of named executive officer compensation, and the frequency of future advisory compensation votes.","company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9811,"accession_number":"0001193125-26-277631","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the complete results of CytomX's Annual Meeting held on June 17, 2026, including voting tallies for seven proposals: election of Class II directors (Matthew P. Young and Elaine V. Jones Ph.D.), ratification of Ernst \u0026 Young LLP as auditor, authorization of additional common shares, amendments to the 2015 equity plan and Employee Stock Purchase Plan, advisory approval of named executive officer compensation, and the frequency of future advisory compensation votes. The detailed vote counts (FOR, AGAINST, ABSTAIN, and broker non-votes) for each proposal are the core disclosure required by Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T21:32:41.171598+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":12844,"run_id":11398,"accession_number":"0001193125-26-277631","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Stockholders approved amendments to the Company's 2015 Equity Incentive Plan (increasing authorized shares by 6.5 million) and the Employee Stock Purchase Plan (increasing authorized shares by 1 million), expanding the pool of shares available for equity compensation and employee stock purchase eligibility.","company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9809,"accession_number":"0001193125-26-277631","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of amendments to the Company's equity incentive plans—the 2015 Equity Incentive Plan (increasing authorized shares by 6.5 million) and the Employee Stock Purchase Plan (increasing authorized shares by 1 million). These are compensatory arrangements affecting equity grants and employee stock purchase eligibility, which fall squarely within the exec_compensation category. The amendments expand the pool of shares available for equity compensation, a material governance and compensation matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T21:32:41.171598+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":12845,"run_id":11398,"accession_number":"0001193125-26-277631","anchor_item_number":"5.03","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"summary":"Stockholders approved a routine amendment to the Company's Certificate of Incorporation to increase authorized common stock shares from 300 million to 600 million at the Annual Meeting on June 17, 2026.","company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9810,"accession_number":"0001193125-26-277631","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure concerns a routine amendment to the Company's Certificate of Incorporation to increase authorized common stock shares from 300 million to 600 million, approved by stockholders at the Annual Meeting on June 17, 2026. While a governance matter, this is a standard administrative action that does not materially affect the registrant's financial condition, operations, or strategic position—it merely expands the pool of shares available for future issuance without creating an immediate dilutive event or material obligation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T21:32:41.171598+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9809,"accession_number":"0001193125-26-277631","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of amendments to the Company's equity incentive plans—the 2015 Equity Incentive Plan (increasing authorized shares by 6.5 million) and the Employee Stock Purchase Plan (increasing authorized shares by 1 million). These are compensatory arrangements affecting equity grants and employee stock purchase eligibility, which fall squarely within the exec_compensation category. The amendments expand the pool of shares available for equity compensation, a material governance and compensation matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T21:32:41.171598+00:00","company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","filing_date":"2026-06-22"},{"id":9810,"accession_number":"0001193125-26-277631","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure concerns a routine amendment to the Company's Certificate of Incorporation to increase authorized common stock shares from 300 million to 600 million, approved by stockholders at the Annual Meeting on June 17, 2026. While a governance matter, this is a standard administrative action that does not materially affect the registrant's financial condition, operations, or strategic position—it merely expands the pool of shares available for future issuance without creating an immediate dilutive event or material obligation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T21:32:41.171598+00:00","company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","filing_date":"2026-06-22"},{"id":9811,"accession_number":"0001193125-26-277631","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the complete results of CytomX's Annual Meeting held on June 17, 2026, including voting tallies for seven proposals: election of Class II directors (Matthew P. Young and Elaine V. Jones Ph.D.), ratification of Ernst \u0026 Young LLP as auditor, authorization of additional common shares, amendments to the 2015 equity plan and Employee Stock Purchase Plan, advisory approval of named executive officer compensation, and the frequency of future advisory compensation votes. The detailed vote counts (FOR, AGAINST, ABSTAIN, and broker non-votes) for each proposal are the core disclosure required by Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T21:32:41.171598+00:00","company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","filing_date":"2026-06-22"}]}